
ResMed (RMD) · Medical Devices
ResMed Q1 FY2027 earnings: summary, key numbers & outlook
Results filed 29 Oct 2026 · Quarter ended 30 Sep 2026
Slides (36 pages)Official transcript (PDF) ↗Press release ↗Investor relations ↗
Summaries and transcripts are machine-generated and can contain errors.
In brief
ResMed closed the MatrixCare divestiture and launched the AirTouch F40 fabric mask, refocusing on core sleep and breathing health and its connected digital ecosystem.
ResMed's quarter was driven by demand for sleep devices and masks in both the Americas and the rest of the world. It launched the AirTouch F40, its third fabric mask, plus the AirCurve 11 ST/ST-A bilevel device in the U.S. It also closed the MatrixCare sale and added partnerships with Eight Sleep and ŌURA to bring more people into sleep care.
Management is steering toward its core sleep and breathing business, a connected ecosystem and its 2030 strategy, backed by about $1.5 billion of planned buybacks and tuck-in M&A of up to about $500 million. The main tension is a second-half squeeze on rest-of-world device sales as the France fleet renewal concludes, plus a roughly 130 bps revenue headwind from Astral.
Slides & documents
Open the slide deck (PDF, 36 pages) ↗
Showing the first 6 of 36 pages.
From ResMed investor relations
- Q1 FY27 Earnings Presentation View Quarterly PresentationSlide deck ↗
- TranscriptCompany's official transcript ↗
SEC filing
Key numbers
- Revenue · GAAP
- $1.4B
- Net income · GAAP
- $418.0M
- Diluted EPS · GAAP
- $2.92
- Non-GAAP diluted EPS · non-GAAP
- $2.91
- Gross margin · GAAP
- 61.5%
- Non-GAAP gross margin · non-GAAP
- 62.5%
- Operating margin · GAAP
- 32.0%
- Non-GAAP operating margin · non-GAAP
- 35.8%
up 6% from a year ago
up 20% from a year ago
up 23% from a year ago
up 14% from a year ago
up 30 bps from a year ago
up 50 bps from a year ago
down 140 bps from a year ago
down 30 bps from a year ago
| Segment or metric | Value | Change |
|---|---|---|
| Americas Sleep Devices | $436.0M | up 8% (6% core constant currency) |
| Americas Masks and other | $397.0M | up 10% |
| Rest of World Sleep Devices | $280.0M | up 12% (13% core constant currency) |
| Rest of World Masks and other | $143.0M | up 12% (11% core constant currency) |
| Total Sleep and Breathing Health | $1.3B | up 8% (7% core constant currency) |
| Residential Care Software | $155.0M | down 7% (up 5% core constant currency) |
Where each number comes from
- Revenue: “Financial Results and Operating Metrics (Unaudited; $ in millions, except for per share amounts) Three Months Ended September 30,2026 | September 30,2025 | % Change | ConstantCurrency (A) Revenue | $1,415 | $1,336 | 6% | 6%”
- Net income: “Operating margin | 32.0% | 33.4% | (140) bps Non-GAAP income from operations (B) | 506 | 482 | 5 Non-GAAP operating margin (B) | 35.8% | 36.1% | (30) bps Net income | 418 | 349 | 20”
- Diluted EPS: “Q1 GAAP diluted earnings per share up 23% to $2.92; non-GAAP diluted EPS up 14% to $2.91”
- Non-GAAP diluted EPS: “Q1 GAAP diluted earnings per share up 23% to $2.92; non-GAAP diluted EPS up 14% to $2.91”
- Gross margin: “Healthy profitability: GAAP gross margin of 61.5%. Non-GAAP gross margin increased 50 basis points to 62.5%, predominantly from productivity pipeline execution.”
- Non-GAAP gross margin: “Non-GAAP gross margin increased 50 basis points to 62.5%, predominantly from productivity pipeline execution.”
- Operating margin: “Robust earnings growth: GAAP operating margin of 32.0% and GAAP diluted earnings per share of $2.92. Non-GAAP operating margin of 35.8% and non-GAAP diluted earnings per share of $2.91”
- Non-GAAP operating margin: “Non-GAAP operating margin of 35.8% and non-GAAP diluted earnings per share of $2.91, up 14% year-over-year, predominantly attributable to strong revenue growth and gross margin improvement.”
- Americas Sleep Devices: “Americas Sleep Devices | $436 | $405 | 8% | 6% Masks and other | 397 | 361 | 10 | 10 Total Sleep | $833 | $766 | 9 | 8”
- Americas Masks and other: “Americas Sleep Devices | $436 | $405 | 8% | 6% Masks and other | 397 | 361 | 10 | 10 Total Sleep | $833 | $766 | 9 | 8”
- Rest of World Sleep Devices: “Rest of World Sleep Devices | $280 | $250 | 12% | 13% Masks and other | 143 | 128 | 12 | 11 Total Sleep | $423 | $378 | 12 | 12”
- Rest of World Masks and other: “Rest of World Sleep Devices | $280 | $250 | 12% | 13% Masks and other | 143 | 128 | 12 | 11 Total Sleep | $423 | $378 | 12 | 12”
- Total Sleep and Breathing Health: “Total Sleep and Breathing Health | $1,260 | $1,169 | 8 | 7 Residential Care Software | 155 | 166 | (7) | 5 Total | $1,415 | $1,336 | 6% | 7%”
- Residential Care Software: “Total Sleep and Breathing Health | $1,260 | $1,169 | 8 | 7 Residential Care Software | 155 | 166 | (7) | 5 Total | $1,415 | $1,336 | 6% | 7%”
Copied from the press release ↗ and other documents in the SEC filing ↗. A figure is published only if its sentence is in those documents.
| From the filing | Q1 FY2027 | vs year ago | vs last quarter |
|---|---|---|---|
| Revenue | $1.4B | +5.9% | −3.3% |
| Operating income | $453.0M | +1.4% | +1.0% |
| Net income | $418.4M | +20.0% | +9.1% |
| Diluted EPS | $2.92 | +23.2% | — |
| Free cash flow | $373.7M | −9.8% | −7.4% |
| Gross margin | 61.5% | +0.3 pts | +2.7 pts |
| Operating margin | 32.0% | −1.4 pts | +1.3 pts |
Calculated by code from XBRL, not by the model.
Outlook
| Metric | Period | Outlook |
|---|---|---|
| Core constant currency revenue growth | fiscal year 2027 | 5 - 7% growth |
| Reported revenue | fiscal year 2027 | $5.75 - $5.85 Billion |
| Non-GAAP diluted EPS | fiscal year 2027 | $12.00 - $12.25 |
Key takeaways
AirTouch F40 extends ResMed's fabric mask line
ResMed launched the AirTouch F40 in the U.S. as its third fabric mask. Its ComfiSoft cushion adapts through the night, and 91% rated it comfortable at initial fitting.
Personalized myAir features aim to lift compliance
Resmed's AI-powered myAir, with the Dawn GenAI coach, reached 2.1M+ inquiries, up 40%. It reports a 4.3% increase in 30-day compliance versus default settings.
MatrixCare exit sharpens focus on core sleep
The MatrixCare sale closed September 1, 2026. Management says it improves the growth, mix and focus of Residential Care Software, whose remaining Brightree and MEDIFOX DAN businesses grew 8%.
GLP-1 data counters fears of lower CPAP demand
An IQVIA analysis of 3,307,000 patients found GLP-1 users were 1170 bps more likely to initiate PAP therapy. Resupply rates were also higher, by 350 bps at 1 year and 730 bps at 3 years.
Partnerships and Nidra widen the patient funnel
Eight Sleep and ŌURA partnerships connect sleep insights to ResMed's assessment and care pathways. ResMed also closed the Nidra restless legs syndrome acquisition on June 1, 2026, and is prioritizing commercial coverage.
Charts
Fourth quarter worked out from the annual figure.
Data
| Q2 FY25 | $1.3B |
| Q3 FY25 | $1.3B |
| Q4 FY25 | $1.3B * |
| Q1 FY26 | $1.3B |
| Q2 FY26 | $1.4B |
| Q3 FY26 | $1.4B |
| Q4 FY26 | $1.5B * |
| Q1 FY27 | $1.4B |
Data
| Q2 FY25 | $2.34 |
| Q3 FY25 | $2.48 |
| Q1 FY26 | $2.37 |
| Q2 FY26 | $2.68 |
| Q3 FY26 | $2.74 |
| Q1 FY27 | $2.92 |
Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.
Data
| Q2 FY25 | 32.5% |
| Q3 FY25 | 33.0% |
| Q4 FY25 | 33.7% |
| Q1 FY26 | 33.4% |
| Q2 FY26 | 34.6% |
| Q3 FY26 | 34.9% |
| Q4 FY26 | 30.7% |
| Q1 FY27 | 32.0% |
Data
| Q2 FY25 | $288.0M |
| Q3 FY25 | $557.9M |
| Q4 FY25 | $508.2M |
| Q1 FY26 | $414.4M |
| Q2 FY26 | $311.2M |
| Q3 FY26 | $520.5M |
| Q4 FY26 | $403.5M |
| Q1 FY27 | $373.7M |
Operating cash flow minus capital expenditure, from cash flow statements.
Questions
What new products did ResMed launch this quarter?
ResMed launched the AirTouch F40, its third fabric CPAP mask, in the U.S. It also introduced the AirCurve 11 ST/ST-A bilevel device and expanded myAir personalization features.
How is ResMed responding to GLP-1 weight-loss drugs?
It points to an IQVIA analysis of 3,307,000 patients showing GLP-1 users were 1170 bps more likely to initiate PAP therapy and had higher resupply rates.
Why did ResMed sell MatrixCare?
Management says the sale accelerates growth and profitability of core Residential Care Software, improves mix and sharpens execution focus. It closed on September 1, 2026.
What is ResMed doing to reach more undiagnosed sleep apnea patients?
It is partnering with Eight Sleep and ŌURA and running marketing campaigns, including one with NASCAR driver Tyler Reddick. In the ŌURA pathway, about 72% of assessment takers were undiagnosed.
What risks does ResMed flag for the rest of fiscal 2027?
It flags second-half pressure on rest-of-world sleep devices as the France fleet renewal concludes, a roughly 130 bps revenue headwind from Astral, and a larger FX headwind of about 60 bps.
Call recording
Call recording on YouTube ↗. Official replay ↗.





